ALGS Aligos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALGS

Price (delayed)

$6.77

Market cap

$84.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.4

Enterprise value

$57.63M

?
Relative Growth: Rel. Growth: 68
Relative Strength: Rel. Strength: 36
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 28
Highlights
The company's debt fell by 49% YoY and by 20% QoQ
Aligos Therapeutics's EPS has increased by 41% YoY and by 16% from the previous quarter
Aligos Therapeutics's net income has increased by 16% QoQ but it has decreased by 2.4% YoY
Aligos Therapeutics's equity has shrunk by 69% YoY
ALGS's quick ratio has dropped by 66% year-on-year and by 13% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aligos.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ALGS

ALGS stock price

How has the Aligos Therapeutics stock price performed over time
Intraday
-3.29%
1 week
22.87%
1 month
6.45%
1 year
-11.5%
YTD
-27.36%
QTD
17.33%

Financial performance

How have Aligos Therapeutics's revenue and profit performed over time
Revenue
$31.52M
Gross profit
$31.52M
Operating income
-$78.99M
Net income
-$75.96M
Gross margin
100%
Net margin
-241%
The company's net margin has surged by 90% YoY and by 87% QoQ
The operating margin has surged by 90% year-on-year and by 88% since the previous quarter
ALGS's operating income is up by 17% since the previous quarter
Aligos Therapeutics's net income has increased by 16% QoQ but it has decreased by 2.4% YoY

Price vs fundamentals

How does ALGS's price correlate with its fundamentals

Growth

What is Aligos Therapeutics's growth rate over time

Valuation

What is Aligos Therapeutics stock price valuation
P/E
N/A
P/B
2.63
P/S
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.83
Aligos Therapeutics's EPS has increased by 41% YoY and by 16% from the previous quarter
The stock's price to book (P/B) is 163% more than its 5-year quarterly average of 1.0 and 88% more than its last 4 quarters average of 1.4
Aligos Therapeutics's equity has shrunk by 69% YoY
The stock's price to sales (P/S) is 92% less than its 5-year quarterly average of 27.3 and 91% less than its last 4 quarters average of 24.7

Efficiency

How efficient is Aligos Therapeutics business performance
Aligos Therapeutics's ROS has soared by 90% YoY and by 88% from the previous quarter
The company's return on invested capital has shrunk by 69% YoY and by 37% QoQ
ALGS's return on assets is down by 38% year-on-year
The return on equity has declined by 30% year-on-year and by 15% since the previous quarter

Dividends

What is ALGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALGS.

Financial health

How did Aligos Therapeutics financials performed over time
The total assets is 93% more than the total liabilities
ALGS's quick ratio has dropped by 66% year-on-year and by 13% since the previous quarter
ALGS's current ratio has dropped by 65% year-on-year and by 14% since the previous quarter
The company's debt is 89% lower than its equity
Aligos Therapeutics's equity has shrunk by 69% YoY
ALGS's debt to equity has soared by 57% YoY but it is down by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.